VALERIO TX overview

Regulatory News: VALERIO THERAPEUTICS (Paris:ALVIO): Name of Director Other offices and functions Julien MIARA Chief Executive Officer and Director Managing Director at Invus Director of Sensorion Director of Versity Jacques MALLET Director and Chairman of the Board Chairman of Gamma-X Corporate Advisory Director of Technoflex Director of the Fournier Majoie Foundation FINANCIERE DE LA MONTAGNE, represented by Nicolas TREBOUTA Director Manager of SARL Financière de la Montagne Manager of SCI...

Regulatory News: Valerio Therapeutics (Paris:ALVIO): Ladies and Gentlemen, We have convened this General Meeting in order to submit for your approval decisions which fall within the remit of both the Ordinary and Extraordinary General Meetings. You are therefore asked to vote on the following agenda: Agenda for the Ordinary General Meeting First resolution : Dismissal of a member of the Board of Directors ( Shefali Agarwal ) Second resolution : Ratification of the co-optation of a member of the...

Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) (the ‘ Company’ ) announces that it has terminated the liquidity agreement entered into on 29 October 2018 with KEPLER CHEUVREUX (the ‘ Agreement’ ). The termination was effective on 19 February 2025. The termination of the Agreement was decided as part of the savings made by the Company given its cash position. The Company does not intend to enter into another liquidity contract at this stage. It should be noted...

Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) today announced a strategic decision to discontinue all clinical trials and associated activities, including the ongoing VIO-01 trial. This shift was decided by the board of directors in the context of the financing challenges of the Company. The Company’s cash position should enable it to finance its refocused business other the next three months. In the meantime, in addition to the reduction of its expenses, it is...

Regulatory News: At its meeting of November 13, 2024, the Board of Directors of Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO ), (“ Valerio Therapeutics ” or the “ Company ”) decided to appoint Mr Julien Miara as CEO and Chairman of the Board of Valerio Therapeutics, succeeding Ms Shefali Argawal, effective immediately. Future evolutions related to the Company’s governance will be announced at a later date. View source version on businesswire.com:...

Regulatory News: Under the liquidity contract entered into between VALERIO THERAPEUTICS (Paris:ALVIO) and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30, 2023: - 287,160 shares - € 156,554.06 - Number of executions on buy side on semester: 509 - Number of executions on sell side on semester: 492 - Traded volume on buy side on semester: 634,648 shares for € 258,705.74 - Traded volume on sell side on semester: 923,185 shares for € 402,719.91 As a...

Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), (“ Onxeo ” or “the Company ”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, announced that the Annual General Meeting held today at 2pm CEST was able to validly deliberate with a quorum of 44.12% , with 30 shareholders representing 49,072,091 voting rights. The Annual General Meeting followed the voting recommendations...